January 1, 2002
Anaheim, CA-The largest trial of cholesterol-lowering therapy ever conducted extends the current indications for statin therapy, reported Rory Collins, MD.  |
January 1, 2002
An agent developed specifically for the treatment of angina reduces the
incidence of major coronary events, reported Henry Dargie, MD, who presented
the results of a trial known as the Impact of Nicorandil in Angina (IONA).
It is believed to be the first large-scale trial to report on the effects
of a specific antianginal drug on clinical outcome. |
January 1, 2002
Ranolazine, the first in a new class of antianginal agents called the partial
fatty acid oxidation (pFOX) inhibitors, improves exercise performance and
reduces angina frequency in patients who still have symptoms despite treatment
with other antianginal medications, according to Bernard Chaitman, MD. He
reported the results of a Phase III study called the Combination Assessment
of Ranolazine in Stable Angina (CARISA). |
June 15, 2009
By:Wayne Kuznar
Dutasteride reduces the risk of biopsy-detectable prostate cancer by approximately one-fourth in men at high risk for the disease without increasing the risk of high-grade cancers, said Gerald L. Andriole, Jr, MD, at the American Urological Association (AUA) 2009 Annual Meeting.
|
June 15, 2009
By:Wayne Kuznar
Sipuleucel-T represents the "first active immunotherapy to demonstrate improvement in overall survival for advanced prostate cancer," said David Penson, MD, MPH, who announced the results of a phase 3 study known as Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT), at the American Urological Association (AUA) 2009 Annual Meeting.
|
May 15, 2009
By:Formulary journal staff
Results from the Regulation of Coagulation in Orthopaedic Surgery to Prevent Deep Vein Thrombosis and Pulmonary Embolism 4 (RECORD4) trial published in Lancet demonstrated that rivaroxaban 10 mg once daily is superior to subcutaneous (SC) enoxaparin in preventing venous thromboembolism (VTE) after total knee arthroplasty.
|
May 15, 2009
By:Christine Blank
Good clinical pharmacy judgment is still the most useful tool in evaluating the prescription needs of seniors, according to speakers at the American College of Clinical Pharmacy (ACCP)/European Society for Clinical Pharmacy (ESCP) International Congress on Clinical Pharmacy meeting in Orlando, Florida, but the pharmacy professionals still reviewed various criteria and methods that can assist in evaluating senior patients, particularly those with cardiovascular disease.
|
May 15, 2009
By:Christine Blank
Prescribing psychotropic medications for attention-deficit/hyperactivity disorder (ADHD) and other disorders in children is common around the world, even though serious adverse drug reactions (ADRs) have been reported with the use of these drugs, said speakers at the American College of Clinical Pharmacy (ACCP)/European Society for Clinical Pharmacy (ESCP) International Congress on Clinical Pharmacy meeting in Orlando, Florida.
|
April 21, 2009
By:Formulary journal staff
Among patients with atrial fibrillation (AF) who are deemed unsuitable for warfarin treatment or who are unwilling to take it, clopidogrel plus aspirin is superior to aspirin alone in preventing vascular events, including strokes, said Stuart Connolly, MD, at the American College of Cardiology 58th Annual Scientific Session.
|
| 
Formulary archives are now available on ModernMedicine.com, a new online resource designed to meet the evolving needs of physicians.